Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Inclusion Criteria: * Histologically or cytologically (or radiologically for patients undergoing curative ablation), newly diagnosed, confirmed HCC and successfully completed curative therapy (resection or ablation) * Imaging to confirm disease-free status within 28 days prior to randomization * ECOG 0-1 at enrolment * Child-Pugh score of 5 or 6 * Adequate organ and marrow function. Exclusion Criteria: * Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC * Evidence of metastasis, macrovascular invasion or co-existing malignant disease on baseline imaging * History of hepatic encephalopathy within 12 months prior to randomization * Evidence, by Investigator assessment, of varices at risk of bleeding on upper endoscopy or contrast-enhanced cross-sectional imaging * Patients with Vp1 to Vp4 portal vein thrombosis on baseline imaging are excluded * Active co-infection with HBV and HDV. * Receipt of prior systemic anticancer therapy for HCC * Those on a waiting list for liver transplantation